Haneen Shalabi, D.O.

Team Member of:
Dr. Shalabi's primary research interests are novel immunotherapy targets for chemo-resistant acute lymphoblastic leukemia. Her clinical focus is the treatment of relapsed/refractory pediatric patients with hematologic malignancies utilizing chimeric antigen receptor (CAR) T cell therapies. Additional areas of interest include neurocognitive effects of immunotherapy in pediatric patients and bone marrow transplantation for patients with malignant and non-malignant diseases.
1) pediatric leukemia, 2) chimeric antigen receptor (CAR) T cell therapy for pediatric leukemia, 3) immunotherapy for relapsed/refractory hematologic malignancies,
4) cognitive effects post immunotherapy
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 1W5890
Bethesda, MD 20892
Ph: 240-858-3339
haneen.shalabi@nih.gov
-
A Phase II Pilot Trial to Estimate Survival After A Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT)
Open - RecruitingNCI Protocol ID NCI-20-C-0042Investigator Haneen Shalabi, D.O.Share this trial: Referral ContactsContact Name Phone Number NCI Pediatric Leukemia Lymphoma BMT Team (240) 760-6970 -
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-067Investigator Haneen Shalabi, D.O.Share this trial: Referral ContactsContact Name Phone Number NCI Pediatric Leukemia Lymphoma BMT Team (240)760-6970
Dr. Shalabi focuses on translation of chimeric antigen receptor therapy to treat high-risk hematologic malignancies in pediatric patients. She works in conjunction with the neurobehavioral team to assess patients receiving immunotherapy for neurocognitive changes.
Selected Key Publications
- Journal of Immunotherapy. 41: 350-358, 2018. [ Journal Article ]
- Hematologica. 103: e215-e218, 2018. [ Journal Article ]
- Frontiers in Pediatrics. 3: 1-12, 2015. [ Journal Article ]
-
Cell-based Therapies: A New Frontier of Personalized Medicine.In: Novel Designs of Early Phase Trials for Cancer Therapeutics. Elsevier Science 2018. [ Book Chapter ]
- Nature Medicine. 24: 20-28, 2018. [ Journal Article ]
Dr. Shalabi received her medical degree in 2010 from Midwestern University, Chicago College of Osteopathic Medicine. In 2013, she completed her pediatric residency in Chicago at Loyola University Medical Center, and then completed her fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington DC in 2016. From 2016-2018, she joined the Pediatric Oncology Branch as an advanced studies fellow with a focus in pediatric cellular therapies.